Comparative Pharmacology
Head-to-head clinical analysis: MANNITOL 5 IN PLASTIC CONTAINER versus OSMITROL 5 IN WATER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANNITOL 5 IN PLASTIC CONTAINER versus OSMITROL 5 IN WATER.
MANNITOL 5% IN PLASTIC CONTAINER vs OSMITROL 5% IN WATER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mannitol is an osmotic diuretic that increases the osmolarity of the glomerular filtrate, reducing tubular reabsorption of water and solutes. It also draws water from intracellular spaces into the extracellular fluid, reducing cerebral edema and intraocular pressure.
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular and interstitial spaces into the extracellular compartment, thereby reducing cerebral edema and intraocular pressure; also promotes diuresis by increasing renal tubular fluid osmolality.
50-100 g intravenously over 30-60 minutes for initial dose in acute renal failure or cerebral edema; maintenance dose 25-50 g every 6-8 hours based on serum osmolality and urine output.
50-100 g intravenously as a 5% solution over 30-60 minutes; may repeat every 6-8 hours as needed. Maximum dose: 200 g in 24 hours.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours (adults with normal renal function); prolonged to 24–48 hours in severe renal impairment.
Approximately 0.25-1.5 hours (15-90 minutes); prolonged in renal impairment or with mannitol accumulation (e.g., in anuria).
Renal: >90% as unchanged drug via glomerular filtration; negligible biliary or fecal elimination.
Primarily renal (90-100% unchanged in urine); negligible biliary or fecal elimination.
Category A/B
Category C
Osmotic Diuretic
Osmotic Diuretic